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Abstract
As a validation study, this study addressed an under-researched area of
bronchopulmonary cancer mortality and incidence. The association between altitude and
bronchopulmonary cancer mortality and incidence was investigated using data from the
Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic
Research. The theoretical framework for my study was Bronfenbrenner’s ecological
model. This model emphasizes the relevance of social and physical environments that
influence patterns of disease and injury and shape responses to these patterns of disease
and injury. The age-adjusted bronchopulmonary cancer mortality and incidence rates per
100,000 people in the highest elevation and lowest elevation states were investigated. The
data used in this study spans from 2006 to 2014. In this study, bivariate statistics were
used to analyze the data. The relevant technique of performing an unpaired t-test was
used. After performing age, gender, and race-stratified analysis, no significant difference
in cancer mortality and incidence was found within the following three groups: Black or
African American, Asian or Pacific Islander, and American Indian or Alaska Native.
This was a new finding, as previous studies did not stratify for race. Cancer mortality
and incidence were found to be lower in both the male and female groups for the highest
elevation states. Cancer mortality and incidence were also found to be lower in all age
categories for the highest elevation states. A positive social change impact of this study
is that this research provides the groundwork for future studies to probe what in the
environment is lowering the bronchopulmonary cancer mortality and incidence for the
White population.
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Chapter 1: Introduction to the Study
Introduction
Cancer is the second leading cause of both morbidity and mortality in the world
(World Health Organization, 2018). In 2012 alone, there were 14 million new cases of
cancer worldwide, and in 2015, almost 9 million people died from cancer worldwide
(World Health Organization, 2018). Therefore, it is important to pay attention to this
disease and learn how to treat it because one out of every six deaths is due to cancer
(World Health Organization, 2018).
After reviewing the literature, I did not find any research on cancer mortality for
site-specific cancers for people living at different altitudes in the years preceding 1982.
However, there are studies dated 1982 and afterwards that show living at higher altitudes
is associated with lower cancer mortality (Amsel, Waterbor, Oler, Rosenwaike, &
Marshall, 1982; Hart, 2011; Simeonov & Himmelstein, 2015). Amsel et al. (1982)
analyzed age-adjusted cancer mortality data from the U.S. Department of Health,
Education, and Welfare for 34 site-specific cancers for the period from 1950 to 1969 as
well as for all cancer sites as a group. They noted lower cancer mortality statistics for
geographic counties characterized by their higher altitudes for tongue and mouth,
esophagus, larynx, melanoma, and lung cancers as well as for all cancer sites as a group
(Amsel et al., 1982).
Other studies have also shown the connection between location and cancer
mortality. Hart (2011) analyzed age-adjusted cancer mortality rates for all cancers from
the CDC from 2001 to 2005 for the six highest elevation states versus the six lowest
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elevation states in the United States. He found that there was a strong association
between low age-adjusted cancer mortality and the highest elevation states for all cancer
sites as a group. Additionally, Simeonov and Himmelstein (2015) used 2005 to 2009
cancer incidence data from the Surveillance, Epidemiology, and End Results (SEER)
Program at the National Cancer Institute (NCI) to search for an association between
cancer incidence and altitude. Simeonov and Himmelstein found an association between
lower incidence of lung cancer (lung and bronchus cancers) and living at higher altitudes.
Simeonov and Himmelstein also found a weak association between lower breast cancer
incidence and living at high altitudes, and they found no association between prostate or
colorectal cancers and altitude. This finding for lung cancer is important because lung
cancer is currently the number one cancer killer in the United States (American Lung
Association, 2017).
Problem Statement
The CDC Wide-ranging Online Data for Epidemiologic Research (WONDER)
portal captures information from 1999 through 2014. For example, Hart (2011) explored
the age-adjusted cancer mortality data from 2001 through 2005 using CDC WONDER
data for all cancers as one single group. Simeonov and Himmelstein (2015) also
explored the age-adjusted lung cancer (lung cancer only, no bronchus cancer) incidence
data from 2005 to 2009 using NCI data. I investigated the association between ageadjusted lung and bronchus cancer (from here on forward, referred to as
bronchopulmonary cancer) mortality rates and altitude by using CDC WONDER data
from 2006 to 2014. I also investigated the association between age-adjusted
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bronchopulmonary cancer incidence rates and altitude by using CDC WONDER data
during the same period.
My study contributes knowledge to a gap in the literature because CDC
WONDER data from 2006 to 2014 is the continuation of the research conducted by Hart
(2011). In my study, I controlled for three confounders: age, sex, and race. A positive
social change impact of this study is that this study provides the groundwork for future
studies to research what in the environment is causing differences in bronchopulmonary
cancer mortality and incidence rates in the United States.
The quantitative analysis used in my study should help in understanding the
nature of the association and the strength of the association between altitude and
bronchopulmonary cancer incidence and mortality rates. In order to address the research
questions, I measured the age-adjusted mortality rates per 100,000 people for
bronchopulmonary cancer in the highest elevation and lowest elevation states. I also
measured the age-adjusted incidence rates per 100,000 people for bronchopulmonary
cancer in the highest and lowest elevation states. I used the same sets of highest and
lowest elevation states that Hart (2011) had used in his study. This will be explained in
detail under the Operational Definitions section of this chapter.
Purpose of the Study
The purpose of my study was to develop the understanding of the association
between altitude and bronchopulmonary cancer mortality and incidence by studying the
cancer mortality data and cancer incidence data for the lowest elevation and highest
elevation states within the United States from 2006 to 2014.
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Research Questions and Hypotheses
Research Question 1: Does bronchopulmonary cancer mortality differ with
increased altitude?
H01: There is no association between altitude and bronchopulmonary cancer
mortality.
H11: There is an association between altitude and bronchopulmonary cancer
mortality.
Research Question 2: Does bronchopulmonary cancer incidence differ with
increased altitude?
H02: There is no association between altitude and bronchopulmonary cancer
incidence.
H12: There is an association between altitude and bronchopulmonary cancer
incidence.
Research Objectives
My first research objective was to answer the first central research question posed
in my dissertation, therefore demonstrating the association between altitude and
incidence of bronchopulmonary cancer. The second research objective was to answer the
second central research question posed in my dissertation, therefore demonstrating the
association between altitude and bronchopulmonary cancer mortality. I controlled for
three confounders: age, sex, and race. These risk factors were the only ones available on
the CDC WONDER health portal.
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Theoretical Foundation
The theoretical framework for my study was Bronfenbrenner’s (1977) ecological
model. This model has been modified to adapt to and be applied to different scenarios
(Satariano, 2006). The ecological model emphasizes the relevance of social and physical
environments that influence patterns of disease and injury and shape responses to these
patterns of disease and injury. The tenets of the ecological model are depicted by the
four levels of influence used in this model, and they serve as the four central components
of this framework. They are the individual level, social environment, physical
environment, and public policy components.
At the individual level, intrapersonal traits that influence behavior are key. The
focus is on changing an individual’s knowledge and attitudes to influence behavior.
Individuals who receive the information on bronchopulmonary cancer incidence and
mortality at higher altitudes might move to higher elevation as a prophylactic against
bronchopulmonary cancer because of their increased awareness. The second level is the
social environment level where interpersonal relationships between friends, colleagues,
peers, family members, and members of the community influence behavior.
The third level is the physical environment level whereby the environment can
have positive or negative influences. Using the methodology explained in the Nature of
the Study section, I studied the age-adjusted rate per 100,000 people for
bronchopulmonary cancer mortality in the highest elevation and lowest elevation states.
The chosen states where I studied bronchopulmonary mortality represent the physical
environment where positive or negative influences might occur. It is at this third central
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component of the physical environment that my methods and measures tie into the
ecological model. I used a similar methodology to study cancer incidence in the highest
elevation and lowest elevation states. Finally, at the public policy level, the focus is on
changing policy to influence behavior. Public health strategies may be implemented to
increase awareness and understanding. The implementation of public health strategies
will further advance the power and the impact of the ecological model.
Nature of Study
I conducted a quantitative study. The research design used in my study is an
ecological study design. In an ecological study, the focus is not on the individual level
but rather on the population or group level. The ecological study design is useful when
measuring prevalence and incidence of disease. It is also both observational and
retrospective. I retrospectively analyzed the 2006 though 2014 data from the CDC.
Operational Definitions
I used the same method that Hart (2011) used to determine the highest and lowest
elevation states. A table from the U.S. Geological Survey displaying states and their
respective lowest and highest elevation points was used. This is key for the internal
validity and reliability of my study. The highest elevation points for Delaware,
Washington, DC, Florida, Louisiana, Mississippi, and Rhode Island are 448, 410, 345,
535, 806, and 812 feet, respectively (U.S. Geological Survey, 2016). This means that all
the other points within each of these lowest elevation states are at an altitude below these
noted highest elevation points (448, 410, 345, 535, 806, and 812 feet). Examining the
highest elevation points for the other 45 states reveals that their highest elevation points
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are higher than those for Delaware, Florida, Louisiana, Mississippi, Rhode Island, and
Washington, DC. Therefore, these six states qualify as the lowest elevation states.
A similar methodology was used in identifying the six highest elevation states.
The lowest elevation points for Colorado, Montana, New Mexico, South Dakota, Utah,
and Wyoming are 3,315; 1,800; 2,842; 966; 2,000; and 3,099 feet, respectively (U.S.
Geological Survey, 2016). This means that the other points within each of these highest
elevation states are at an altitude above these noted lowest elevation points (3,315; 1,800;
2,842; 966; 2,000; and 3,099 feet). The lowest elevation points for the other 45 states are
lower than the lowest elevation points of Colorado, Montana, New Mexico, South
Dakota, Utah, and Wyoming. Therefore, these six states qualify as the highest elevation
states.
Assumptions
The CDC has a useful public health information portal called Wide-ranging
Online Data for Epidemiologic Research (WONDER) (CDC, 2017) that allows the user
to interactively request age-adjusted cancer mortality and age-adjusted cancer incidence
data for different kinds of cancers. This public health information portal is practical and
interactive. It allows someone to input qualifiers such as type of cancer, time frame of
interest, and specific state of interest within the United States. The age-adjusted cancer
incidence and age-adjusted cancer mortality data in units of number of people per
100,000 can then be requested and obtained online. I assumed that all the data provided
by the CDC WONDER portal are accurate, as my research results are based on the data
from this public health information portal.
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It was also assumed that one of the best methods to perform this study is to use
the entire population data set of all the selected highest elevation states and lowest
elevation states versus specific population types within the selected states. From a
statistical analysis point of view, I was able to harness the most amount of data from the
CDC WONDER portal by using the entire population of the selected states. This is the
reason why Hart (2011) also chose to collect and analyze the data from the entire
population of the same highest elevation and same lowest elevation states.
Scope and Delimitations
The specific parameters used in my study were bronchopulmonary cancer
incidence and bronchopulmonary cancer mortality along with altitude. My dissertation
was focused on the association between altitude and bronchopulmonary cancer mortality
and bronchopulmonary cancer incidence. I closed the gap in the literature by using new
data. Moreover, I controlled the data for three confounders of sex, age, and race to
observe and verify if there are differences in association for the various combinations of
different groups. What the scope of this dissertation does not cover is an entire list of
possible environmental factors that may be responsible for the lower rate of
bronchopulmonary cancer mortality and incidence in higher altitudes. In addition to
behavioral and lifestyle factors, there may be other responsible environmental factors
such as better quality of water and food supply and perhaps even decreases in stress
levels.
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Limitations
Eighty percent of lung cancer deaths are attributed to tobacco smoking (American
Cancer Society, 2018), though genetics are thought to be the reason why some people
develop particular kinds of cancer. However, genetics alone are not considered to be the
cause of that many lung cancers (American Cancer Society, 2018). One of the limitations
of this study is that I did not control for smoking status, which is a behavioral and
lifestyle factor.
Possible environmental factors such as lower air pollution levels (Pope et al.,
2002), lower oxygen levels (Simeonov & Himmelstein, 2015), higher radiation levels
(Scott & Di Palma, 2006), and higher vitamin D intake (Hayes, 2010) are suggested to be
potential reasons for explaining differences in bronchopulmonary cancer incidence and
bronchopulmonary mortality at different altitudes. However, I did not expound on these
potential causes of bronchopulmonary cancer incidence and cancer mortality, focusing on
the association between altitude and bronchopulmonary cancer incidence and mortality
for new data. Another limitation of this study is that an association between altitude and
bronchopulmonary cancer incidence and mortality does not imply causality or mean that
altitude is a major influencer on bronchopulmonary cancer incidence and mortality.
Moreover, my study does not account for lifestyle (such as tobacco use) or higher
population densities, which lead to increased air pollution due to increased use of motor
vehicles, watercrafts, and aircrafts.
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Significance of the Study
My research is a validation study conducted to address an under-researched area
of bronchopulmonary cancer mortality and incidence. My research design was useful for
the findings of my research inquiry. The results of my study provide insight concerning
how living at different elevations is associated with different bronchopulmonary cancer
mortality and incidence using new data for the United States. I used the quantitative
research design to amass new knowledge for the advancement of this area of study.
My research inquiry is significant because it contributes to the expansion and
development of a body of knowledge. This study provides the groundwork for future
studies to research what environmental factors cause differences in bronchopulmonary
cancer mortality and incidence in the United States. My study also contributes to positive
social change through an ecological model. The immediacy of the positive social change
is brought about through the relevance of the individual component and social
environment component of the ecological model. Both the individual and social circles
influence patterns of disease and injury. The individual and social environment both
shape responses to these patterns of disease and injury.
At the individual level, the focus is on changing an individual’s knowledge and
attitudes to influence behavior. Individuals may learn of the information concerning
lower bronchopulmonary cancer incidence and mortality at higher altitudes. They may
relocate to higher elevation as a prophylactic against bronchopulmonary cancer due to
their increased awareness of this issue which may bring about an immediate positive
social change.
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At the social environment level, interpersonal relationships between friends,
colleagues, peers, family members, and members of the community influence behavior.
The immediate positive social change, through the web of these interpersonal networks
and structures, expands and impacts even more people through this social arrangement
and framework.
However, if individuals carry on lifestyles that are correlated with negative health
outcomes (e.g., smoking) then the benefits of living at higher altitudes may not be able to
counteract against the detriments of these lifestyles. Therefore, lifestyle must be factored
for in determining the benefits of moving to a higher elevation.
Summary and Transition
The CDC WONDER data that I analyzed runs from 2006 through 2014. This
chapter included the problem statement, purpose of the study, research questions,
limitations of the study, and significance of the study. The following chapter
demonstrates an extensive review of the literature regarding cancer mortality and
incidence and their association with altitude.
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Chapter 2: Literature Review
Introduction
This chapter presents an overview of the research that had been done concerning
cancer incidence and cancer mortality rates with respect to variations in altitude. The
primary purpose of the following literature review was to research previous studies and to
determine a research gap in the literature that is appropriate for my study.
Literature Review
Using CDC data from 2001 through 2005, Hart (2011) found that for the six
lowest elevation states in the United States, the calculated age-adjusted mean cancer
mortality rate for all cancer sites as a group was 205 cancer deaths per 100,000 people,
and the calculated age-adjusted mean cancer mortality rate was 171 cancer deaths per
100,000 people for the six states with the highest altitudes. These statistics demonstrated
a statistically significant difference for cancer mortality between the six lowest elevation
states and the six highest elevation states. Hart did not discuss lung cancer incidence.
Burtscher (2014) also indicated that residing at higher elevations is associated with lower
mortality from stroke, cardiovascular disease, and bronchopulmonary cancer. Simeonov
and Himmelstein (2015) used 2005-2009 cancer incidence data from the NCI, and they
found a strong inverse association between lung cancer incidence and altitude. However,
Simeonov and Himmelstein did not discuss lung cancer mortality in a similar way that
Hart (2011) did not discuss lung cancer incidence.
Hart (2010) also investigated the cancer mortality rates due to all cancers in low
elevation counties in the state of Texas and compared them with the mortality rates due to
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all cancers in high elevation counties and medium elevation counties within the same
state. A county with 75% or more of its terrain in the 0-250 feet above sea level range
was classified as a low elevation county. A county with 75% or more of its terrain in the
1,000-2,000 feet above sea level range was classified as a medium elevation county.
Finally, a county with 75% or more of its terrain higher than 3,000 feet above sea level
was classified as high elevation county. Cancer mortality due to all cancers was found to
be statistically significant between the high and low elevation counties with a p-value of
0.003. Cancer mortality due to all cancers was also found to be statistically significant
between the high and medium elevation counties with a p-value of 0.010. Cancer
mortality due to all cancers was not found to be statistically significant between the low
and medium elevation counties with a p-value of 0.05.
The final study by Hart (2013), whose investigation formed the basis of this
study, was also focused on the association between cancer mortality and land elevation in
American counties and cities but with another method. In this scholarly article, he used
median elevation data derived from the U.S. Geological Survey and the U.S. Department
of Agriculture. This study was concentrated on three variables that are correlated with
elevation. They are natural background radiation, oxygen concentration, and barometric
pressure (Hart, 2013). Cities and counties that were at high elevation had higher natural
background radiation than their counterparts at low elevation. This study showed an
inverse correlation between natural background radiation and cancer mortality as a whole
(not site-specific). Cities and counties that were at high elevation had lower oxygen
concentration and lower barometric pressure than their counterparts at low elevation.
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This study showed direct correlation between natural background radiation and cancer
mortality as a whole. Whether it was the higher natural background radiation, lower
oxygen concentration, lower barometric pressure, or a combination of the three factors
that was responsible for the lower cancer mortality rate, was beyond the scope of this
study.
Winkelmayer, Hurley, Liu, and Brookhart (2012) studied the association of
altitude with cardiovascular disease for dialysis patients in the United States. Close to
one million patients were followed. All of these patients initiated dialysis sometime
during the period of time from 1995 to 2006. Compared to similar patients living at or
near sea level, patients residing at altitudes greater than or equal to 6,000 feet,
experienced a 31% decrease in myocardial infarction, a 27% decrease in strokes, and a
19% decrease in death associated with cardiovascular disease.
Hayes (2010) provided evidence that the enhancement of vitamin D with
increasing altitude could explain the observed decrease in cancer rates at higher altitudes.
Scott and Di Palma (2006) suggested that elevated diagnostic medical radiation and
natural background radiation may lead to lower cancer mortality through the radiation
hormesis process. (Increased rock concentration with altitude is associated with
increased background radiation.) Sung et al. (2011) were the first to show in a controlled
demonstration in mice that lower levels of oxygen delay tumorigenesis. They were able
to control for other confounding variables such as radiation exposure and barometric
pressure. Tao et al. (2000) researched cancer mortality rates from all cancers in high
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background radiation areas of Yangjiang, China, during the period of time from 1979
through 1995 and found that they were generally lower than in the control region.
Danaei et al. (2005) found that the causes of bronchopulmonary cancer are
smoking, low fruit and vegetable intake, indoor smoke from household use of solid fuels,
and urban air pollution. Pope et al. (2002) found that exposure over time to combustible
air pollution can cause cardiopulmonary and lung cancer. Samet et al. (2009) stated that
an increased level of outdoor air pollution can be responsible for an increase in lung
cancer incidence, however, they cannot provide a reliable estimate of risk based on the
available data. Subramanian and Govindan (2007) noted that an increase in cancer risk is
associated with air pollution. In Europe, it is estimated that 1-3.6% of lung cancer
incidence may be associated with air pollution for the general population, and the data
increases to 5-7% for those that never smoked.
Cesaroni et al. (2013) studied chronic exposure to metropolitan air pollution and
its effect on mortality. The study used a cohort of greater than one million adult subjects
in Rome, Italy. In particular, Cesaroni et al. (2013) investigated the causal relationship
between nitrogen dioxide and fine particulate matter to mortality. They were able to
assess the concentration-response relationship. The most robust relationship was
established for cardiac ischemia. It was then followed by cardiovascular illness and lung
cancer. The results of this study will have a profound effect on the next wave of policy
changes regarding air quality in the European Union.
Siegel, Ma, Zou, and Jemal (2014) stated that even though cancer mortality has
been on the decline for the last two decades, further social positive change can be
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accelerated by reinforcing existing cancer control knowledge to the population especially
to those with low socioeconomic status.
Information from by the Lung Institute provides biological reasons why it may be
beneficial to live at higher altitudes. At higher elevations, the lungs expand compared to
lower elevations. The expansion allows the lungs to contribute more to beneficial body
functions and processes. The lung expansion enables the body to produce more red blood
cells which are essential in promoting good health. More capillaries are produced which
allows the lungs to efficiently bring oxygen to the cardiovascular system (Lung Institute,
2016).
Research Gap in the Literature
The CDC WONDER data that I have analyzed runs from 2006 through 2014. I
have investigated the age-adjusted cancer mortality phenomenon further by using more
current CDC data starting where Hart had left off in 2005. I have investigated the ageadjusted cancer incidence phenomenon by using CDC data to compare with the 2005 to
2009 NCI data used by Simeonov and Himmelstein (2015). These two items that have
been investigated comprise the identified research gap in the literature.
Theoretical Foundation
The theoretical framework for my study is Bronfenbrenner’s (1977) ecological
model. This model has since been modified over time in order to adapt to and be applied
to different scenarios (Satariano, 2006). The ecological model emphasizes four
components that greatly influence patterns of disease and injury and strongly shape our
responses to these patterns of disease and injury. The tenets of the ecological model are
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depicted by the four levels of influence used in this model, and they serve as the four
central components of this framework. They are the individual level, social environment,
physical environment, and public policy components.
At the individual level, intrapersonal traits that influence behavior are key. The
focus is on changing an individual’s knowledge and attitudes to influence behavior.
Characteristics of this first level are personal knowledge, demographics, beliefs, values,
aptitude, conduct, self-awareness, and self-respect. Individuals may learn of the
information on lower bronchopulmonary cancer incidence and mortality at higher
altitudes. On processing the information, they might move to higher elevation as a
prophylactic against bronchopulmonary cancer because of their increased awareness.
They simply may just want to seek an environment for themselves that are conducive to
great health benefits.
The second level is the social environment level where interpersonal relationships
between friends, colleagues, peers, family members, and members of the community
influence behavior. Characteristics of this second level are social structure, social
foundation, family structure, work structure, neighborhood network, friendship network,
and peer structure.
The third level is the physical environment level whereby the environment can
have positive or negative influences. Characteristics of this third level are climate,
habitat, setting, situation, ambiance, elevation, and terrain. I have studied the ageadjusted rate per 100,000 people for bronchopulmonary cancer mortality and
bronchopulmonary cancer incidence in the highest elevation and lowest elevation states.
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The chosen states where I have studied the bronchopulmonary mortality and incidence
represent the physical environment where positive or negative influences might occur. It
is at this third central component of the physical environment that my methods and
measures tie into the ecological model. Individuals tend to avoid an environment where
they may be susceptible to maladies such as cancer. This may possibly include relocating
from a low elevation environment to a high elevation environment in order to harness any
health benefits.
Finally, at the public policy level, the focus is on changing policy in order to
influence behavior. Public health strategies may be implemented to increase awareness
and understanding. Characteristics of this fourth level are regulations, protocols, tariffs,
government agencies, and codes. Without the implementation of public health strategies,
it may be difficult to witness the power and impact of the ecological model. These multilevel interventions are theorized to be very effective in bringing forth a positive social
change impact leading to a better tomorrow with positive health outcomes.
Summary
In Chapter 2, I performed the literature review of my research topic and then
identified a research gap in the literature. I also described the theoretical foundation of
my research. In Chapter 3, I will discuss the research methods and statistical analysis
used in my study.
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Chapter 3: Research Method
Introduction
This chapter consists of a description of my research methodology. The four
main parts of my methodology are research design, sampling, collection of data, and
analysis of data. The description of the research design explains why I selected this study
design. I illustrate what was involved in the sampling process. Finally, I also delineate
the entire data collection process concluding with a comprehensive analysis of the data in
my study.
Research Questions
Research Question 1: Does bronchopulmonary cancer mortality differ with
increased altitude?
H01: There is no association between altitude and bronchopulmonary cancer
mortality.
H11: There is an association between altitude and bronchopulmonary cancer
mortality.
Research Question 2: Does bronchopulmonary cancer incidence differ with
increased altitude?
H02: There is no association between altitude and bronchopulmonary cancer
incidence.
H12: There is an association between altitude and bronchopulmonary cancer
incidence.
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Design of the Study
The goal of my research design was to make sure that the data collected allowed
me to effectively and systematically answer my research questions. Obtaining data that
was specific to my research questions required that I understand the significance of an
observable phenomenon, which would justify my study design. The research design used
in my study is an ecological study design with a quantitative approach. It is also both
observational and retrospective. The quantitative analysis used in my study helped to
understand the nature of the association and the extent of the association between altitude
and bronchopulmonary cancer mortality and incidence. Being able to better understand
the association between altitude and bronchopulmonary cancer incidence and mortality
rates is one of the strengths of my study design. This same study design has a weakness
in that it does not help establish causality.
Original Study Design
Hart (2011) identified the six highest elevation states in his article to be Colorado,
Montana, New Mexico, South Dakota, Utah, and Wyoming. He also identified the six
lowest elevation states to be Delaware, Florida, Louisiana, Mississippi, Rhode Island, and
Washington, DC. I used the same method that Hart used to determine the highest and
lowest elevation states using a table from the U.S. Geological Survey displaying states
and their respective lowest and highest elevation points. The highest elevation points for
Delaware, Florida, Louisiana, Mississippi, Rhode Island, and Washington, DC are 448,
345, 535, 806, 812, and 410 feet respectively (U.S. Geological Survey, 2016). This
means that all of the other points within each of these lowest elevation states are at an
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altitude below these noted highest elevation points. The highest elevation points for other
states were all higher than the highest elevation points of these six states, making them
the six lowest elevation states.
A similar methodology was used in identifying the six highest elevation states.
The lowest elevation points for Colorado, Montana, New Mexico, South Dakota, Utah,
and Wyoming are 3315, 1800, 2842, 966, 2000, and 3099 feet respectively (U.S.
Geological Survey, 2016). This means that all of the other points within each of these
highest elevation states are at an altitude above these noted lowest elevation points (3315,
1800, 2842, 966, 2000, and 3099 feet). The lowest elevation points for other states were
all lower than the lowest elevation points of these six states, making them the six highest
elevation states.
My study contributes knowledge to the research gap in the literature because I
analyzed new data from the CDC ranging from 2006 to 2014. I controlled for three
possible confounders of age, sex, and race, which had not been done previously.
Sampling
My research involves the entire population of six states that have been selected as
highest elevation states and the entire population of six states that have been selected as
lowest elevation states. Therefore, the sample population used in my study is the entire
population of these chosen states.
Data Sources and Variables
I used secondary data from the CDC in my study. This study was focused on the
2006 through 2014 age-adjusted cancer incidence data and the 2006 through 2014 age-
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adjusted cancer mortality rates from the CDC. The independent variables used are the
names of the six highest elevation states and the names of the six lowest elevations. The
dependent variables are bronchopulmonary cancer incidence rates and bronchopulmonary
cancer mortality rates.
Data Collection
The CDC has a very useful public health information portal called WONDER
(CDC, 2017) that allows the user to interactively request age-adjusted cancer incidence
and age-adjusted cancer mortality data for different kinds of cancers. This public health
information portal is very practical and interactive. One can input qualifiers such as type
of cancer, time frame of interest, and specific state of interest within the United States.
The age-adjusted cancer incidence and age-adjusted cancer mortality data in units of
number of people per 100,000 can then be requested and obtained online.
The CDC WONDER portal captures information from 2006 through 2014. Hart
(2011) used CDC data from 2001 through 2005 and found a statistically significant
difference for cancer mortality between the six lowest elevation states and the six highest
elevation states within the U.S. I have investigated the age-adjusted cancer mortality
phenomenon further by starting where Hart had stopped in 2005 by researching the CDC
bronchopulmonary cancer mortality data from 2006 through 2014. Simeonov and
Himmelstein (2015) used 2005-2009 cancer incidence data from the NCI, and they found
a very strong inverse association between lung cancer incidence and altitude. I also have
investigated the age-adjusted cancer incidence phenomenon by using the CDC lung and
bronchus cancer incidence data from 2006 through 2014.
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Data Analysis
The purpose of my study is to further develop the understanding of the association
between altitude and bronchopulmonary cancer mortality and incidence by studying the
bronchopulmonary cancer mortality data and the bronchopulmonary cancer incidence
data for the highest elevation and lowest elevation states within the United States from
2006 to 2014. I have controlled for 3 confounders of age, sex, and race as they were the
only risk factor that were available on the CDC WONDER. Even the CDC data are all
age-adjusted, I still further stratified my analysis by age, using 3 different age groups, to
detect any significant differences in cancer mortality and incidence within each age group
for the highest and elevation states.
In this study, bivariate statistics were used to analyze the data. The relevant
technique of performing an unpaired t-test was used. The independent variables are the
names of the six highest elevation states and the names of the six lowest elevations. The
dependent variables are bronchopulmonary cancer incidence rates and bronchopulmonary
cancer mortality rates.
This test contrasts the disparity between the two selected categories of elevation
states. The company GraphPad Software has a software application that is perfectly
suitable for analyzing my data (GraphPad, 2018). The software is called “Quick Calcs
Online Calculator for Scientists.” I used this calculator in this study to calculate the pvalue resulting from the comparison between these two groups of data using the t-test.
The age-adjusted cancer incidence rates per 100,000 from the six highest elevation states
from 2006-2014 were investigated. They were compared to the age-adjusted cancer
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incidence rate per 100,000 from the six lowest elevation states during the same period
from 2006-2014. I controlled for the 3 confounders age, sex, and race.
The null hypothesis related to my first research question is that there is no
difference between the bronchopulmonary cancer mortality rates from the highest
elevation states when compared to the bronchopulmonary cancer mortality rates from the
lowest elevation states. The alternative hypothesis is that there is a statistically
significant difference between the two groups of cancer mortality. If the p-value is less
than 0.05, then the null hypothesis should be rejected. With the null hypothesis
dismissed, the alternative hypothesis is then applicable to the results of the study. It
should be more completely stated as the observed difference between bronchopulmonary
cancer mortality from the highest elevation states and the bronchopulmonary cancer
mortality from the lowest elevation states, is statistically significant (Gertsman, 2008).
Bivariate statistics were used again to analyze the data for cancer incidence. The
age-adjusted cancer incidence rates per 100,000 from the six highest elevation states from
2006-2014 were investigated. They were compared to the age-adjusted cancer incidence
rates per 100,000 from the six lowest elevation states during the same period from 20062014. I also controlled for the 3 confounders of age, sex, and race.
The null hypothesis related to my second research question is that there is no
difference between the bronchopulmonary cancer incidence rates from the highest
elevation states when compared to the bronchopulmonary cancer incidence rates from the
lowest elevation states. The alternative hypothesis is that there is a statistically
significant difference between the two groups of cancer incidence. If the p-value is less
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than 0.05, then the null hypothesis should be rejected. With the null hypothesis
dismissed, the alternative hypothesis is then applicable to the results of the study. It
should be more completely stated as the observed difference between bronchopulmonary
cancer incidence from the highest elevation states and the bronchopulmonary incidence
from the lowest elevation states, is statistically significant (Gertsman, 2008).
Summary
The research design associated with my study, sampling, collection of data, and
analysis of data are described in this chapter. The research design used in my study is an
ecological study design. It is also both observational and retrospective. It takes a
quantitative approach as data from the CDC WONDER public health information portal
is used to further develop the understanding of the association between altitude and
bronchopulmonary cancer mortality and incidence by studying the cancer mortality data
and cancer incidence data for the lowest elevation and highest elevation states within the
United States from 2006 to 2014. The data was controlled for age, sex, and race.
The bivariate statistical technique of conducting an unpaired t-test is used to
analyze the data in this study. This test compares the difference between the
bronchopulmonary cancer mortality of the two groups of elevation states in order to
determine a p-value which allows for the scientific rejection of the null hypothesis if
there is a statistically significant difference between the two groups. It also compares the
difference between the bronchopulmonary cancer incidence of the two groups of
elevation states in order to determine a p-value which allows for the scientific rejection of
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the null hypothesis. This brings a conclusion to my proposal. The next section, Chapter
4, deals with data collection and data analysis.
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Chapter 4: Results
Introduction
My purpose in conducting this quantitative, observational, retrospective
ecological study, was to measure the association between altitude and bronchopulmonary
cancer. This study was also undertaken to answer the following two research questions:
Research Question 1: Does bronchopulmonary cancer mortality differ with
increased altitude?
Research Question 2: Does bronchopulmonary cancer incidence differ with
increased altitude?
In this chapter, I describe the process of collecting secondary data from the CDC.
I include an explanation of the sample population that is used in my study. Lastly, I
illustrate my data analysis well-defined tables.
Data Collection
I received Walden University’s Institutional Review Board (IRB) approval to
conduct this study on October 17, 2017 (approval number 10-17-17-0074351). I used the
secondary from the CDC public health information portal called WONDER (CDC,
2017). This public health information portal allows the user to interactively request ageadjusted cancer incidence and age-adjusted cancer mortality data for different kinds of
cancers. I collected data on bronchopulmonary cancer.
The CDC WONDER portal captures information from 2006 through 2014. Hart
(2011) used CDC data from 2001 through 2005 and found a statistically significant
difference for cancer mortality between the six lowest elevation states and the six highest
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elevation states within the United States. The six lowest elevation states are Delaware,
Florida, Louisiana, Mississippi, Rhode Island, and Washington, DC. The six highest
elevation states are Colorado, Montana, New Mexico, South Dakota, Utah, and
Wyoming. I further investigated the association between altitude and cancer mortality by
researching the CDC bronchopulmonary cancer mortality data from 2006 through 2014,
which is the time right after the time studied by Hart. Additionally, Simeonov and
Himmelstein (2015) used 2005-2009 cancer incidence data from the NCI and found a
strong inverse association between lung cancer incidence and altitude. Therefore, I also
investigated the association between altitude and cancer incidence by using the CDC
bronchopulmonary cancer incidence data from 2006 through 2014.
Sample Population
The sample population used in my study is the entire population of chosen states
selected to represent the lowest elevation states and the highest elevation states. My
research involves the entire population of six states that have been selected as the highest
elevation states and the entire population of six states that have been selected as the
lowest elevation states.
Controlling for Possible Confounders
In addition to continuing the work conducted by Hart (2011) and Simeonov and
Himmelstein (2015), I elevated this research study by controlling for possible risk factors
such as age, sex, and race. I categorized the entire population of each chosen state
according the following age range: 44 years and younger, 45-64 years, and 65 years and
older. For sex, I divided the entire population of each chosen state into the male and
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female genders. Finally, I divided the entire population each chosen state into four
categories of race: White, Black or African American, Asian or Pacific Islander, and
American Indian or Alaska Native.
Results for Cancer Mortality
Female Cancer Mortality
The age-adjusted cancer mortality rates per 100,000 for the six highest elevation
states from 2006-2014 are displayed in Table 1 for the entire female population in those
states. They are compared to the entire female, age-adjusted cancer mortality rate per
100,000 for the six lowest elevation states during the same period.
Table 1
Female Bronchopulmonary Cancer Mortality, 2006-2014

Highest elevation states
Colorado
Montana
New Mexico
South Dakota
Utah
Wyoming
Totals
Lowest elevation states
Delaware
Washington, DC
Florida
Louisiana
Mississippi
Rhode Island
Totals

Deaths

Population

Age-adjusted mortality rate per
100,000

6,898
2,229
3,006
1,633
1,672
961
16,399

22,615,514
4,437,389
9,304,585
3,671,332
12,342,595
2,472,442
54,843,857

29.5
38.6
27.3
34.8
16.3
34.4
28.3

2,372
1,056
47,180
10,054
6,682
2,736
70,080

4,173,344
2,891,757
87,155,387
20,757,395
13,712,010
4,905,070
133,594,963

44.9
34.6
37.0
42.5
41.5
42.2
38.5
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Male Cancer Mortality
The age-adjusted cancer mortality rates per 100,000 for the six highest elevation
states from 2006-2014 are displayed in Table 2 for the entire male population in those
states. They are compared to the entire male, age-adjusted cancer mortality rate per
100,000 for the six lowest elevation states during the same period.
Table 2
Male Bronchopulmonary Cancer Mortality, 2006-2014

Highest elevation states
Colorado
Montana
New Mexico
South Dakota
Utah
Wyoming
Totals
Lowest elevation states
Delaware
Washington, DC
Florida
Louisiana
Mississippi
Rhode Island
Totals

Deaths

Population

Age-adjusted mortality
rate per 100,000

7,442
2,483
3,622
2,244
2,246
1,120
19,157

22,756,887
4,471,606
9,095,302
3,683,308
12,463,500
2,567,794
55,038,397

39.8
49.5
40.5
58.2
25.8
45.7
40.2

2,678
1,221
59,903
14,212
10,884
2,970
91,868

3,919,404
2,596,108
83,366,874
19,848,574
12,946,292
4,589,221
127,266,473

64.3
56.1
57.5
76.6
88.7
62.2
62.8

Ages 44 and Younger Cancer Mortality
The age-adjusted cancer mortality rates per 100,000 for the six highest elevation
states from 2006-2014 are displayed in Table 3 for the entire ages 44 and younger
population in those states. They are compared to the entire ages 44 and younger, ageadjusted cancer mortality rate per 100,000 for the six lowest elevation states during the
same period.
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Table 3
Ages 44 and Younger Bronchopulmonary Cancer Mortality, 2006-2014

Highest elevation states
Colorado
Montana
New Mexico
South Dakota
Utah
Wyoming
Totals
Lowest elevation states
Delaware
Washington, DC
Florida
Louisiana
Mississippi
Rhode Island
Totals

Deaths

Population

Age-adjusted mortality rate per
100,000

118
27
45
20
50
18
278

23,382,087
5,019,498
11,091,784
4,377,849
17,622,464
3,011,736
69,505,418

0.5
0.6
0.5
0.5
0.4
0.7
0.5

49
22
938
291
216
71
1,587

4,723,070
3,598,013
95,079,789
24,952,570
16,393,233
5,498,392
150,245,067

1.1
0.7
1.0
1.4
1.5
1.4
1.1

Ages 45 to 64 Cancer Mortality
The age-adjusted cancer mortality rates per 100,000 for the six highest elevation
states from 2006-2014 are displayed in Table 4 for the entire ages 45 to 64 population in
those states. They are compared to the entire ages 45 to 64, age-adjusted cancer mortality
rate per 100,000 for the six lowest elevation states during the same period.
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Table 4
Ages 45 to 64 Bronchopulmonary Cancer Mortality, 2006-2014

Highest elevation states
Colorado
Montana
New Mexico
South Dakota
Utah
Wyoming
Totals
Lowest elevation states
Delaware
Washington, DC
Florida
Louisiana
Mississippi
Rhode Island
Totals

Deaths

Population

Age-adjusted mortality rate per
100,000

3,659
1,116
1,480
941
1,101
511
8,808

11,898,006
2,543,993
4,812,297
1,911,295
4,897,551
1,366,558
27,449,700

28.4
38.7
27.4
44.5
21.0
32.9
29.2

1,381
769
26,826
7,737
5,612
1,485
43,810

2,178,521
1,264,262
45,451,086
10,553,092
6,779,579
2,606,142
68,832,682

58.2
56.5
53.6
68.0
76.4
53.0
58.2

Ages 65 and Older Cancer Mortality
The age-adjusted cancer mortality rates per 100,000 for the six highest elevation
states from 2006-2014 are displayed in Table 5 for the entire ages 65 and older
population in those states. They are compared to the entire ages 65 and older, ageadjusted cancer mortality rate per 100,000 for the six lowest elevation states during the
same period.
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Table 5
Ages 65 and Older Bronchopulmonary Cancer Mortality, 2006-2014

Highest elevation states
Colorado
Montana
New Mexico
South Dakota
Utah
Wyoming
Totals
Lowest elevation states
Delaware
Washington, DC
Florida
Louisiana
Mississippi
Rhode Island
Totals

Deaths

Population

Age-adjusted mortality rate per
100,000

10,563
3,569
5,103
2,916
2,767
1,552
26,470

5,092,308
1,345,504
2,495,806
1,065,496
2,286,080
641,942
12,927,136

216.1
272.5
211.5
273.4
124.3
249.8
211.1

3,620
1,486
79,319
16,238
11,738
4,150
116,551

1,191,157
655,590
29,991,386
5,100,307
3,485,490
1,389,757
41,783,687

312.4
242.1
265.6
325.0
343.9
296.8
281.5

White Cancer Mortality
The age-adjusted cancer mortality rates per 100,000 for the six highest elevation
states from 2006-2014 are displayed in Table 6 for the entire White population in those
states. They are compared to the entire White, age-adjusted cancer mortality rate per
100,000 for the six lowest elevation states during the same period.
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Table 6
White Bronchopulmonary Cancer Mortality, 2006-2014

Highest elevation states
Colorado
Montana
New Mexico
South Dakota
Utah
Wyoming
Totals
Lowest elevation states
Delaware
Washington, DC
Florida
Louisiana
Mississippi
Rhode Island
Totals

Deaths

Population

Age-adjusted mortality rate per
100,000

13,518
4,483
6,328
3,635
3,766
2,032
33,762

40,787,703
8,138,562
15,560,336
6,444,469
23,162,746
4,769,629
98,863,445

34.1
42.9
34.7
44.0
20.6
39.5
33.7

4,285
476
97,978
17,524
12,663
5,495
138,421

5,906,272
2,316,627
135,813,917
26,295,358
16,204,647
8,310,100
194,846,921

54.3
27.6
47.5
56.1
61.6
51.4
49.7

Black or African American Cancer Mortality
The age-adjusted cancer mortality rates per 100,000 for the six highest elevation
states from 2006-2014 are displayed in Table 7 for the entire Black or African American
population in those states. They are compared to the entire Black or African American,
age-adjusted cancer mortality rate per 100,000 for the six lowest elevation states during
the same period. The data for Montana, South Dakota, and Wyoming are suppressed by
the CDC because the absolute number of bronchopulmonary cancer mortality cases for
Black or African Americans are extremely low because the Black or African American
population in those states are very low. This was done to protect the identity of the
people involved since it may be relatively easy to guess who they are (CDC, 2017).
Going forward, there will be suppressed data in some more tables for the same reason.
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However, the totals in each table reflect the total number of deaths for the entire table,
which indicate how many deaths there had been in each of the individual states.
Table 7
Black or African American Bronchopulmonary Cancer Mortality, 2006-2014

Highest elevation states
Colorado
Montana
New Mexico
South Dakota
Utah
Wyoming
Totals
Lowest elevation states
Delaware
Washington, DC
Florida
Louisiana
Mississippi
Rhode Island
Totals

Deaths

Population

Age-adjusted mortality rate per
100,000

529
Suppressed
133
Suppressed
41
Suppressed
734

2,219,493
68,946
519,423
130,948
379,072
75,330
3,393,212

40.1
Suppressed
40.9
Suppressed
33.9
Suppressed
38.9

711
1,774
8,234
6,570
4,831
151
22,271

1,838,424
2,909.549
28,864,160
13,270,198
10,022,814
763,987
57,669,132

49.9
53.8
37.7
61.2
61.0
33.5
48.7

Asian or Pacific Islander Cancer Mortality
The age-adjusted cancer mortality rates per 100,000 for the six highest elevation
states from 2006-2014 are displayed in Table 8 for the entire Asian or Pacific Islander
population in those states. They are compared to the entire Asian or Pacific Islander,
age-adjusted cancer mortality rate per 100,000 for the six lowest elevation states during
the same period.
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Table 8
Asian or Pacific Islander Bronchopulmonary Cancer Mortality, 2006-2014

Highest elevation states
Colorado
Montana
New Mexico
South Dakota
Utah
Wyoming
Totals
Lowest elevation states
Delaware
Washington, DC
Florida
Louisiana
Mississippi
Rhode Island
Totals

Deaths

Population

Age-adjusted mortality rate per
100,000

206
Suppressed
53
Suppressed
85
Suppressed
372

1,553,745
76,279
342,929
86,195
854,164
52,930
2,966,242

22.1
Suppressed
20.9
Suppressed
20.1
Suppressed
21.8

36
24
736
118
50
42
1,006

291,937
225,590
4,945,089
719,583
274,769
326,711
6,783,679

22.9
20.2
20.2
27.6
34.0
24.6
21.6

American Indian or Alaska Native Cancer Mortality
The age-adjusted cancer mortality rates per 100,000 for the six highest elevation
states from 2006-2014 are displayed in Table 9 for the entire American Indian or Alaska
Native population in those states. They are compared to the entire American Indian or
Alaska Native, age-adjusted cancer mortality rate per 100,000 for the six lowest elevation
states during the same period.
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Table 9
American Indian or Alaskan Native Bronchopulmonary Cancer Mortality, 2006-2014

Highest elevation states
Colorado
Montana
New Mexico
South Dakota
Utah
Wyoming
Totals
Lowest elevation states
Delaware
Washington, DC
Florida
Louisiana
Mississippi
Rhode Island
Totals

Deaths

Population

Age-adjusted mortality rate per
100,000

87
207
114
222
26
32
688

811,460
625,208
1,977,199
693,028
410,113
142,347
4,659,335

23.7
63.9
9.5
75.7
17.6
52.0
28.2

18
Suppressed
135
54
22
18
250

56,115
36,099
899,095
320,830
156,072
93,493
1,561,704

51.4
Suppressed
20.5
25.4
21.7
34.7
23.5

All non-White Cancer Mortality
Since all of the data for the non-White races demonstrated no significant
difference between the highest elevation states and the lowest elevations states, it is
imperative that we sum up the cancer mortality data from the three races of Black or
African American, Asian or Pacific Islander, and American Indian or Alaska Native, to
see if the summed data still show no statistically significant difference between the
highest elevation states and the lowest elevations states.
The age-adjusted cancer mortality rates per 100,000 for the six highest elevation
states from 2006-2014 are displayed in Table 10 for the entire non-White population in
those states. They are compared to the entire non-White, age-adjusted cancer mortality
rate per 100,000 for the six lowest elevation states during the same period. As it is

38
noticeable in the following table, there is no suppressed data, because of the higher
cancer mortality statistics collected.
Table 10
All Non-White Bronchopulmonary Cancer Mortality, 2006-2014

Highest elevation states
Colorado
Montana
New Mexico
South Dakota
Utah
Wyoming
Totals
Lowest elevation states
Delaware
Washington, DC
Florida
Louisiana
Mississippi
Rhode Island
Totals

Deaths

Population

Age-adjusted mortality rate per
100,000

822
229
300
242
152
49
1,794

4,584,698
770,433
2,839,551
910,171
1,643,349
270,607
11,018,809

31.1
58.4
16.7
65.0
21.8
34.7
29.6

765
1,801
9,105
6,742
4,903
211
23,527

2,186,476
3,171,238
34,708,344
14,310,611
10,453,655
1,184,191
66,014,515

46.5
52.3
34.6
59.0
60.0
31.2
45.3

Results for Cancer Incidence
Female Cancer Incidence
The age-adjusted cancer incidence rates per 100,000 for the six highest elevation
states from 2006-2014 are displayed in Table 11 for the entire female population in those
states. They are compared to the entire female, age-adjusted cancer incidence rate per
100,000 for the six lowest elevation states during the same period.
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Table 11
Female Bronchopulmonary Cancer Incidence, 2006-2014

Highest elevation states
Colorado
Montana
New Mexico
South Dakota
Utah
Wyoming
Totals
Lowest elevation states
Delaware
Washington, DC
Florida
Louisiana
Mississippi
Rhode Island
Totals

Cases

Population

Age-adjusted incidence rate per
100,000

10,068
3,177
4,089
2,263
2,435
1,265
23,297

22,615,514
4,437,389
9,304,585
3,671,332
12,342,595
2,472,442
54,843,857

43.0
55.4
37.2
49.6
23.7
44.8
40.2

3,400
1,467
68,796
13,390
9,052
4,054
100,159

4,173,344
2,891,757
87,155,387
20,757,395
13,712,010
4,905,070
133,594,963

64.7
49.0
55.1
56.6
56.5
64.4
56.0

Male Cancer Incidence
The age-adjusted cancer incidence rates per 100,000 for the six highest elevation
states from 2006-2014 are displayed in Table 12 for the entire male population in those
states. They are compared to the entire male, age-adjusted cancer incidence rate per
100,000 for the six lowest elevation states during the same period.
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Table 12
Male Bronchopulmonary Cancer Incidence, 2006-2014

Highest elevation states
Colorado
Montana
New Mexico
South Dakota
Utah
Wyoming
Totals
Lowest elevation states
Delaware
Washington, DC
Florida
Louisiana
Mississippi
Rhode Island
Totals

Cases

Population

Age-adjusted incidence rate per
100,000

10,024
3,313
4,617
2,831
2,992
1,349
25,126

22,756,887
4,471,606
9,095,302
3,683,308
12,463,500
2,567,794
55,038,397

52.0
65.2
50.2
72.8
33.7
53.0
51.5

3,632
1,632
79,155
18,043
13,575
3,955
119,992

3,919,404
2,596,108
83,366,874
19,848,574
12,946,292
4,589,221
127,266,473

86.0
72.4
75.7
94.9
107.7
82.2
81.3

Ages 44 and Younger Cancer Incidence
The age-adjusted cancer incidence rates per 100,000 for the six highest elevation
states from 2006-2014 are displayed in Table 13 for the entire ages 44 and younger
population in those states. They are compared to the entire ages 44 and younger, ageadjusted cancer incidence rate per 100,000 for the six lowest elevation states during the
same period.
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Table 13
Ages 44 and Younger Bronchopulmonary Cancer Incidence, 2006-2014

Highest elevation states
Colorado
Montana
New Mexico
South Dakota
Utah
Wyoming
Totals
Lowest elevation states
Delaware
Washington, DC
Florida
Louisiana
Mississippi
Rhode Island
Totals

Cases

Population

Age-adjusted incidence rate per
100,000

281
76
101
47
117
30
652

28,382,087
5,019,498
11,091,784
4,377,849
17,622,464
3,011,736
69,505,418

1.1
1.7
1.1
1.3
0.9
1.1
1.1

109
63
1,882
524
343
122
3,043

4,723,070
3,598,013
95,079,789
24,952,570
16,393,233
5,498,392
150,245,067

2.5
2.1
2.1
2.4
2.5
2.3
2.2

Ages 45 to 64 Cancer Incidence
The age-adjusted cancer incidence rates per 100,000 for the six highest elevation
states from 2006-2014 are displayed in Table 14 for the entire ages 45 to 64 population in
those states. They are compared to the entire ages 45 to 64, age-adjusted cancer
incidence rate per 100,000 for the six lowest elevation states during the same period.
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Table 14
Ages 45 to 64 Bronchopulmonary Cancer Incidence, 2006-2014

Highest elevation states
Colorado
Montana
New Mexico
South Dakota
Utah
Wyoming
Totals
Lowest elevation states
Delaware
Washington, DC
Florida
Louisiana
Mississippi
Rhode Island
Totals

Cases

Population

Age-adjusted incidence rate per
100,000

5,836
1,706
2,307
1,410
1,680
797
13,736

11,898,006
2,543,993
4,812,297
1,911,295
4,897,551
1,386,558
27,449,700

45.4
59.3
43.0
67.3
32.1
51.4
45.8

2,117
1,190
41,806
11,068
7,986
2,421
66,588

2,178,521
1,264,262
45,451,086
10,553,092
6,779,579
2,606,142
68,832,682

89.5
87.3
83.9
97.4
108.9
86.5
88.7

Ages 65 and Older Cancer Incidence
The age-adjusted cancer incidence rates per 100,000 for the six highest elevation
states from 2006-2014 are displayed in Table 15 for the entire ages 65 and older
population in those states. They are compared to the entire ages 65 and older, ageadjusted cancer incidence rate per 100,000 for the six lowest elevation states during the
same period.

43
Table 15
Ages 65 and Older Bronchopulmonary Cancer Incidence, 2006-2014

Highest elevation states
Colorado
Montana
New Mexico
South Dakota
Utah
Wyoming
Totals
Lowest elevation states
Delaware
Washington, DC
Florida
Louisiana
Mississippi
Rhode Island
Totals

Cases

Population

Age-adjusted incidence rate per
100,000

13,975
4,708
6,298
3,637
3,630
1,787
34,035

5,092,308
1,345,504
2,495,806
1,065,496
2,286,080
641,942
12,927,136

284.8
358.6
259.1
346.0
162.2
286.2
270.7

4,806
1,846
104,263
19,841
14,298
5,466
150,520

1,191,157
625,590
29,991,386
5,100,307
3,485,490
1,389,757
41,783,687

413.4
301.2
350.7
394.9
415.9
400.8
364.4

White Cancer Incidence
The age-adjusted cancer incidence rates per 100,000 for the six highest elevation
states from 2006-2014 are displayed in Table 16 for the entire White population in those
states. They are compared to the entire White, age-adjusted cancer incidence rate per
100,000 for the six lowest elevation states during the same period.
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Table 16
White Bronchopulmonary Cancer Incidence, 2006-2014

Highest elevation states
Colorado
Montana
New Mexico
South Dakota
Utah
Wyoming
Totals
Lowest elevation states
Delaware
Washington, DC
Florida
Louisiana
Mississippi
Rhode Island
Totals

Cases

Population

Age-adjusted incidence rate per
100,000

18,867
6,057
8,272
4,754
5,178
2,549
45,677

40,787,703
8,138,562
15,560,336
6,444,469
23,162,746
4,769,629
98,863,445

46.9
57.9
45.0
58.4
27.9
48.6
45.2

5,926
651
134,191
22,724
16,387
7,640
187,519

5,906,272
2,316,627
135,813,917
26,295,358
16,204,647
8,310,100
194,846,921

75.2
36.9
66.0
72.4
79.3
72.6
68.0

Black or African American Cancer Incidence
The age-adjusted cancer incidence rates per 100,000 for the six highest elevation
states from 2006-2014 are displayed in Table 17 for the entire Black or African American
population in those states. They are compared to the entire Black or African American,
age-adjusted cancer incidence rate per 100,000 for the six lowest elevation states during
the same period.
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Table 17
Black or African American Bronchopulmonary Cancer Incidence, 2006-2014

Highest elevation states
Colorado
Montana
New Mexico
South Dakota
Utah
Wyoming
Totals
Lowest elevation states
Delaware
Washington, DC
Florida
Louisiana
Mississippi
Rhode Island
Totals

Cases

Population

Age-adjusted incidence rate per
100,000

697
17
185
17
61
Suppressed
988

2,219,493
68,946
519,423
130,948
379,072
75,330
3,393,212

50.7
77.9
54.1
32.0
50.6
Suppressed
50.4

1,008
2,358
11,343
8,467
6,141
266
29,583

1,838,424
2,909,549
28,864,160
13,270,198
10,022,814
763,987
57,669,132

69.1
71.5
50.7
77.0
76.0
56.5
63.2

Asian or Pacific Islander Cancer Incidence
The age-adjusted cancer incidence rates per 100,000 for the six highest elevation
states from 2006-2014 are displayed in Table 18 for the entire Asian or Pacific Islander
population in those states. They are compared to the entire Asian or Pacific Islander,
age-adjusted cancer incidence rate per 100,000 for the six lowest elevation states during
the same period.
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Table 18
Asian or Pacific Islander Bronchopulmonary Cancer Incidence, 2006-2014

Highest elevation states
Colorado
Montana
New Mexico
South Dakota
Utah
Wyoming
Totals
Lowest elevation states
Delaware
Washington, DC
Florida
Louisiana
Mississippi
Rhode Island
Totals

Cases

Population

Age-adjusted incidence rate per
100,000

348
22
74
Suppressed
122
Suppressed
587

1,553,745
76,279
342,929
86,195
854,164
52,930
2,966,242

35.5
44.0
26.9
Suppressed
28.9
Suppressed
32.9

Suppressed
49
1,049
182
70
44
1,453

291,937
225,590
4,945,089
719,583
274,769
326,711
6,783,679

Suppressed
38.5
26.6
38.1
43.4
25.0
28.7

American Indian or Alaska Native Cancer Incidence
The age-adjusted cancer incidence rates per 100,000 for the six highest elevation
states from 2006-2014 are displayed in Table 19 for the entire American Indian or Alaska
Native population in those states. They are compared to the entire American Indian or
Alaska Native, age-adjusted cancer incidence rate per 100,000 for the six lowest
elevation states during the same period.
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Table 19
American Indian or Alaska Native Bronchopulmonary Cancer Incidence, 2006-2014

Highest elevation states
Colorado
Montana
New Mexico
South Dakota
Utah
Wyoming
Totals
Lowest elevation states
Delaware
Washington, DC
Florida
Louisiana
Mississippi
Rhode Island
Totals

Cases

Population

Age-adjusted incidence rate per
100,000

102
387
154
311
32
43
1,029

811,460
625,208
1,977,199
693,028
410,113
142,347
4,659,355

25.3
111.7
12.6
101.0
21.2
55.5
39.9

Suppressed
Suppressed
140
50
23
Suppressed
249

56,115
36,099
899,095
320,830
156,072
93,493
1,561,704

Suppressed
Suppressed
20.9
22.4
24.5
Suppressed
22.7

All non-White Cancer Incidence
Since all of the data for the non-White races demonstrated no significant
difference between the highest elevation states and the lowest elevations states, it is
imperative that we sum up the cancer incidence data from the three races of Black or
African American, Asian or Pacific Islander, and American Indian or Alaska Native, to
see if the summed data still show no statistically significant difference between the
highest elevation states and the lowest elevations states.
The age-adjusted cancer incidence rates per 100,000 for the six highest elevation
states from 2006-2014 are displayed in Table 20 for the entire non-White population in
those states. They are compared to the entire non-White, age-adjusted cancer incidence
rate per 100,000 for the six lowest elevation states during the same period. As it is
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noticeable in the following table, there is no suppressed data, because of the higher
cancer incidence statistics collected.
Table 20
All Non-White Bronchopulmonary Cancer Incidence, 2006-2014

Highest elevation states
Colorado
Montana
New Mexico
South Dakota
Utah
Wyoming
Totals
Lowest elevation states
Delaware
Washington, DC
Florida
Louisiana
Mississippi
Rhode Island
Totals

Cases

Population

Age-adjusted incidence rate per
100,000

1,147
426
413
340
215
63
2,604

4,584,698
770,433
2,839,551
910,171
1,643,349
270,607
11,018,809

41.4
101.7
22.0
87.3
30.6
38.8
41.0

1,085
2,411
12,532
8,699
6,234
324
31,285

2,186,476
3,171,238
34,708,344
14,310,611
10,453,655
1,184,191
66,014,515

64.1
69.7
46.3
74.2
74.7
45.6
58.8

Data Analysis for Cancer Mortality
The bivariate statistical technique of conducting an unpaired t-test is used for
comparing the bronchopulmonary cancer mortality rates between highest elevation states
and the lowest elevation states. The Quick Calcs Online Calculator for Scientists was
used to calculate the p-value resulting from the comparison between these two groups of
data.
Female Cancer Mortality
The unpaired t-test contrasts the disparity between the female cancer mortality
data for the highest elevation states and lowest elevation states. The p-value is calculated
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to be 0.0166, which by conventional criteria, indicates that there is a statistically
significant difference between these two groups. The female bronchopulmonary cancer
mortality is lower in the highest elevation states than in the lowest elevation states.
Male Cancer Mortality
The unpaired t-test contrasts the disparity between the male cancer mortality data
for the highest elevation states and lowest elevation states. The p-value is calculated to
be 0.0051, which by conventional criteria, indicates that there is a very statistically
significant difference between these two groups. The male bronchopulmonary cancer
mortality is much lower in the highest elevation states than in the lowest elevation states.
Ages 44 and Younger Cancer Mortality
The unpaired t-test contrasts the disparity between the age 44 and younger cancer
mortality data for the highest elevation states and lowest elevation states. The p-value is
calculated to be 0.0006, which by conventional criteria, indicates that there is an
extremely statistically significant difference between these two groups. The ages 44 and
younger bronchopulmonary cancer mortality is very much lower in the highest elevation
states than in the lowest elevation states.
Ages 45 to 64 Cancer Mortality
The unpaired t-test contrasts the disparity between the age 45 to 64 cancer
mortality data for the highest elevation states and lowest elevation states. The p-value is
calculated to be 0.0001, which by conventional criteria, indicates that there is an
extremely statistically significant difference between these two groups. The ages 45 to
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64 bronchopulmonary cancer mortality is very much lower in the highest elevation states
than in the lowest elevation states.
Ages 65 and Older Cancer Mortality
The unpaired t-test contrasts the disparity between the age 65 and older cancer
mortality data for the highest elevation states and lowest elevation states. The p-value is
calculated to be 0.0244, which by conventional criteria, indicates that there is a
statistically significant difference between these two groups. The ages 65 and older
bronchopulmonary cancer mortality is lower in the highest elevation states than in the
lowest elevation states.
White Cancer Mortality
The unpaired t-test contrasts the disparity between the white cancer mortality data
for the highest elevation states and lowest elevation states. The p-value is calculated to
be 0.0434, which by conventional criteria, indicates that there is a statistically significant
difference between these two groups. The white bronchopulmonary cancer mortality is
lower in the highest elevation states than in the lowest elevation states.
Black or African American Cancer Mortality
The unpaired t-test contrasts the disparity between the white cancer mortality data
for the highest elevation states and lowest elevation states. The p-value is calculated to
be 0.1598, which by conventional criteria, indicates that there is no statistically
significant difference between these two groups.
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Asian or Pacific Islander Cancer Mortality
The unpaired t-test contrasts the disparity between the Asian or Pacific Islander
population cancer mortality data for the highest elevation states and lowest elevation
states. The p-value is calculated to be 0.2597, which by conventional criteria, indicates
that there is no statistically significant difference between these two groups.
American Indian or Alaska Native Cancer Mortality
The unpaired t-test contrasts the disparity between the American Indian or Alaska
Native cancer mortality data for the highest elevation states and lowest elevation states.
The p-value is calculated to be 0.4862, which by conventional criteria, indicates that there
is no statistically significant difference between these two groups.
All non-White Cancer Mortality
The unpaired t-test contrasts the disparity between the non-White cancer mortality
data for the highest elevation states and lowest elevation states. The p-value is calculated
to be 0.3461, which by conventional criteria, indicates that there is no statistically
significant difference between these two groups. Therefore, we just reconfirmed that the
cancer mortality data for three races of Black or African American, Asian or Pacific
Islander, and American Indian or Alaska Native, as a group, show no statistically
significant difference for the highest elevation states and lowest elevation states.
Data Analysis for Cancer Incidence
The bivariate statistical technique of conducting an unpaired t-test is used for
comparing the bronchopulmonary cancer incidence rates between highest elevation states
and the lowest elevation states. The Quick Calcs Online Calculator for Scientists was

52
used to calculate the p-value resulting from the comparison between these two groups of
data.
Female Cancer Incidence
The unpaired t-test contrasts the disparity between the female cancer incidence
data for the highest elevation states and lowest elevation states. The p-value is calculated
to be 0.0129, which by conventional criteria, indicates that there is a statistically
significant difference between these two groups. The female bronchopulmonary cancer
incidence is lower in the highest elevation states than in the lowest elevation states.
Male Cancer Incidence
The unpaired t-test contrasts the disparity between the male cancer incidence data
for the highest elevation states and lowest elevation states. The p-value is calculated to
be 0.0019, which by conventional criteria, indicates that there is a very statistically
significant difference between these two groups. The male bronchopulmonary cancer
incidence is much lower in the highest elevation states than in the lowest elevation states.
Ages 44 and Younger Cancer Incidence
The unpaired t-test contrasts the disparity between the age 44 and younger cancer
incidence data for the highest elevation states and lowest elevation states. The p-value is
calculated to be 0.0001, which by conventional criteria, indicates that there is an
extremely statistically significant difference between these two groups. The ages 44 and
younger bronchopulmonary cancer incidence is very much lower in the highest elevation
states than in the lowest elevation states.
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Ages 45 to 64 Cancer Incidence
The unpaired t-test contrasts the disparity between the age 45 to 64 cancer
incidence data for the highest elevation states and lowest elevation states. The p-value is
calculated to be 0.0001, which by conventional criteria, indicates that there is an
extremely statistically significant difference between these two groups. The ages 45 to
64 bronchopulmonary cancer incidence is very much lower in the highest elevation states
than in the lowest elevation states.
Ages 65 and Older Cancer Incidence
The unpaired t-test contrasts the disparity between the age 65 and older cancer
incidence data for the highest elevation states and lowest elevation states. The p-value is
calculated to be 0.0178, which by conventional criteria, indicates that there is a
statistically significant difference between these two groups. The ages 65 and older
bronchopulmonary cancer incidence is lower in the highest elevation states than in the
lowest elevation states.
White Cancer Incidence
The unpaired t-test contrasts the disparity between the White cancer incidence
data for the highest elevation states and lowest elevation states. The p-value is calculated
to be 0.0299, which by conventional criteria, indicates that there is a statistically
significant difference between these two groups. The white bronchopulmonary cancer
incidence is lower in the highest elevation states than in the lowest elevation states.
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Black or African American Cancer Incidence
The unpaired t-test contrasts the disparity between the Black or African American
cancer incidence data for the highest elevation states and lowest elevation states. The pvalue is calculated to be 0.1286, which by conventional criteria, indicates that there is no
statistically significant difference between these two groups.
Asian or Pacific Islander Cancer Incidence
The unpaired t-test contrasts the disparity between the Asian or Pacific Islander
cancer incidence data for the highest elevation states and lowest elevation states. The pvalue is calculated to be 0.9284, which by conventional criteria, indicates that there is no
statistically significant difference between these two groups.
American Indian or Alaska Native Cancer Incidence
The unpaired t-test contrasts the disparity between the American Indian or Alaska
Native cancer incidence data for the highest elevation states and lowest elevation states.
The p-value is calculated to be 0.2518, which by conventional criteria, indicates that there
is no statistically significant difference between these two groups.
All non-White Cancer Incidence
The unpaired t-test contrasts the disparity between the non-White cancer
incidence data for the highest elevation states and lowest elevation states. The p-value is
calculated to be 0.5551, which by conventional criteria, indicates that there is no
statistically significant difference between these two groups. Therefore, we just
reconfirmed that the cancer incidence data for three races of Black or African American,
Asian or Pacific Islander, and American Indian or Alaska Native, as a group, show no
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statistically significant difference for the highest elevation states and lowest elevation
states.
Summary
In Chapter 4, I presented the findings of my research and data analyses. I also
describe the systematic application of my research methods. In Chapter 5, I will
summarize my research findings, discuss the implications for practice, explain the social
impact, and make recommendations for future research.
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Chapter 5: Discussion, Conclusions, and Recommendations
Introduction
The purpose of this study was to develop the understanding of the association
between altitude and bronchopulmonary cancer mortality and incidence by studying the
cancer mortality data and cancer incidence data for the lowest elevation and highest
elevation states within the United States from 2006 to 2014. In this final chapter, I
summarize my research findings, discuss the implications for practice, explain the social
impact, and make recommendations for future research.
Summary and Interpretation of Findings
Although Hart (2011) and Simeonov & Himmelstein (2015) have pointed out
statistically significant differences in cancer mortality and incidence between areas of
high elevation and areas of low elevation, my findings refute their findings for certain
races. In the following paragraphs, I demonstrate how controlling for a possible
confounder such as race led to my findings.
Using CDC data from 2001 through 2005, Hart (2011) found that for the six
lowest elevation states in the United States, the calculated age-adjusted mean cancer
mortality rate for all cancer sites as a group was 205 cancer deaths per 100,000 people,
and the calculated age-adjusted mean cancer mortality rate was 171 cancer deaths per
100,000 people for the six states with the highest elevation. These statistics demonstrated
a statistically significant lower cancer mortality rate for the six highest elevation states
when compared to the six lowest elevation states. Hart did not discuss cancer incidence.
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Simeonov and Himmelstein (2015) addressed the cancer incidence that Hart
(2011) did not. They used 2005-2009 lung cancer incidence data from the NCI and
demonstrated a statistically significant lower lung cancer incidence rate for areas of high
altitude when compared to areas of low altitude. However, Simeonov and Himmelstein
did not discuss lung cancer mortality.
My study was a continuation of the work that had been done by Hart (2011) and
Simeonov and Himmelstein (2015) using new CDC data to fill the gap in the literature.
As a result of controlling for such founders such as sex, age, and race, new findings
emerged. The following paragraphs include detailed descriptions of my findings for the
bronchopulmonary cancer mortality data when controlled for these three confounders.
Female Cancer Mortality
The p-value is 0.0166, which by conventional criteria indicates that there is a
statistically significant difference between the highest elevation states and lowest
elevation states. The female bronchopulmonary cancer mortality is lower in the highest
elevation states than in the lowest elevation states. Results were similar for males.
Male Cancer Mortality
The p-value is 0.0051, which by conventional criteria indicates that there is a very
statistically significant difference between the highest elevation states and lowest
elevation states. The male bronchopulmonary cancer mortality is much lower in the
highest elevation states than in the lowest elevation states. Both male and female results
show lower cancer mortality among high altitude dwellers. Therefore, gender may not be
affecting the relationship between cancer mortality and altitude.
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Ages 44 and Younger Cancer Mortality
The p-value is 0.0006, which by conventional criteria indicates that there is an
extremely statistically significant difference between the highest elevation states and
lowest elevation states. The ages 44 and younger bronchopulmonary cancer mortality is
much lower in the highest elevation states than in the lowest elevation states. This trend
also appeared in other age groups.
Female Ages 45 to 64 Cancer Mortality
The p-value is 0.0001, which by conventional criteria indicates that there is an
extremely statistically significant difference between the highest elevation states and
lowest elevation states. Similar to the 44 and younger group, the ages 45 to 64
bronchopulmonary cancer mortality is much lower in the highest elevation states than in
the lowest elevation states. The final age group also showed similar results.
Ages 65 and Older Cancer Mortality
The p-value is 0.0244, which by conventional criteria indicates that there is a
statistically significant difference between the highest elevation states and lowest
elevation states. The ages 65 and older bronchopulmonary cancer mortality is lower in
the highest elevation states than in the lowest elevation states. All three age categories
showed lower cancer mortality among high altitude dwellers. Therefore, age may not be
affecting the relationship between cancer mortality and altitude.
White Cancer Mortality
The p-value is 0.0434, which by conventional criteria indicates that there is a
statistically significant difference between the highest elevation states and lowest
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elevation states. The white bronchopulmonary cancer mortality is lower in the highest
elevation states than in the lowest elevation states. This coincides with the findings for
age and gender.
Black or African American Cancer Mortality
The p-value is 0.1598, which by conventional criteria indicates that there is no
statistically significant difference between the highest elevation states and lowest
elevation states. This was first time during the analysis of the bronchopulmonary cancer
mortality data where I discovered a new finding. This finding refutes the findings by
Hart (2011) because he did not control for confounders such as race. Thus, the
interpretation is that for Blacks or American Americans, altitude has no influence on their
bronchopulmonary cancer mortality.
Asian or Pacific Islander Cancer Mortality
The p-value is 0.2597, which by conventional criteria indicates that there is no
statistically significant difference between the highest elevation states and lowest
elevation states. Thus, the interpretation is that for Asians or Pacific Islanders altitude
has no influence on their bronchopulmonary cancer mortality. Note that the p-value is
slightly higher for Asian or Pacific Islander when compared to Blacks or American
Americans. This means that there is even less of a difference found for the Asian or
Pacific Islander group.
American Indian or Alaska Native Cancer Mortality
The p-value is 0.4862, which by conventional criteria indicates that there is no
statistically significant difference between the highest elevation states and lowest
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elevation states. Thus, the interpretation is that for American Indians or Alaska Natives
altitude has no influence on their bronchopulmonary cancer mortality. Note that the pvalue is the highest for American Indians or Alaska Natives when compared to the other
races. This means that there is the least amount of difference found for the American
Indian or Alaska Native group.
All non-White Cancer Mortality
The p-value is 0.3461, which by conventional criteria indicates that there is no
statistically significant difference between the highest elevation states and lowest
elevation states. This reconfirms that the cancer mortality data for three races of Black or
African American, Asian or Pacific Islander, and American Indian or Alaska Native, as a
group, show no statistically significant difference for the highest elevation states and
lowest elevation states. These are unique findings considering that these three groups of
races would need to be excluded from groups that would benefit from lower
bronchopulmonary cancer mortality at higher altitudes.
Female Cancer Incidence
The p-value is 0.0129, which by conventional criteria indicates that there is a
statistically significant difference between the highest elevation states and lowest
elevation states. The female bronchopulmonary cancer incidence is lower in the highest
elevation states than in the lowest elevation states. These results coincide with the results
for cancer mortality and are also seen in the male group for cancer incidence.
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Male Cancer Incidence
The p-value is 0.0019, which by conventional criteria indicates that there is a very
statistically significant difference between the highest elevation states and lowest
elevation states. The male bronchopulmonary cancer incidence is much lower in the
highest elevation states than in the lowest elevation states. Both male and female results
show lower cancer incidence among high altitude dwellers; therefore, like the results for
cancer mortality, gender may not be affecting the relationship between cancer incidence
and altitude.
Ages 44 and Younger Cancer Incidence
The p-value is 0.0001, which by conventional criteria indicates that there is an
extremely statistically significant difference between the highest elevation states and
lowest elevation states. The ages 44 and younger bronchopulmonary cancer incidence is
much lower in the highest elevation states than in the lowest elevation states. Similar to
gender, the age groups showed similar results for cancer incidence that were shown for
cancer mortality.
Ages 45 to 64 Cancer Incidence
The p-value is 0.0001, which by conventional criteria indicates that there is an
extremely statistically significant difference between the highest elevation states and
lowest elevation states. The ages 45 to 64 bronchopulmonary cancer incidence is much
lower in the highest elevation states than in the lowest elevation states. The final age
group also showed similar results.
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Ages 65 and Older Cancer Incidence
The p-value is 0.0178, which by conventional criteria indicates that there is a
statistically significant difference between the highest elevation states and lowest
elevation states. The ages 65 and older bronchopulmonary cancer incidence is lower in
the highest elevation states than in the lowest elevation states. All three age categories
showed lower cancer incidence among high altitude dwellers. Therefore, age may not be
affecting the relationship between cancer incidence and altitude, which was also the case
for cancer mortality.
White Cancer Incidence
The p-value is 0.0299, which by conventional criteria indicates that there is a
statistically significant difference between the highest elevation states and lowest
elevation states. The white bronchopulmonary cancer incidence is lower in the highest
elevation states than in the lowest elevation states. This coincides with the cancer
incidence findings for age and gender.
Black or African American Cancer Incidence
The p-value is 0.1286, which by conventional criteria indicates that there is no
statistically significant difference between the highest elevation states and lowest
elevation states. Like cancer mortality, this was first time during the analysis of the
bronchopulmonary cancer incidence data where I discovered a new finding. This finding
refutes the findings by Simeonov and Himmelstein (2015) because they did not control
for confounders such as race. Therefore, the interpretation is that for Blacks or American
Americans altitude has no influence on their bronchopulmonary cancer incidence.
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American Indian or Alaska Native Cancer Incidence
The p-value is 0.2518, which by conventional criteria, indicates that there is no
statistically significant difference between the highest elevation states and lowest
elevation states. Therefore, the interpretation is that for American Indians or Alaska
Natives, altitude has no influence on their bronchopulmonary cancer incidence. Note that
the p-value is slightly higher for American Indians or Alaska Natives when compared to
Blacks or African Americans. This means that there is even less of a difference found for
the American Indian or Alaska Native group.
Asian or Pacific Islander Cancer Incidence
The p-value is 0.9284, which by conventional criteria, indicates that there is no
statistically significant difference between the highest elevation states and lowest
elevation states. Therefore, the interpretation is that for Asians or Pacific Islanders,
altitude has no influence on their bronchopulmonary cancer incidence. Note that the pvalue is the highest for Asians or Pacific Islanders when compared to the other races.
This means that there is the least amount of difference found for the Asian or Pacific
Islander group.
All non-White Cancer Incidence
The p-value is 0.5551, which by conventional criteria, indicates that there is no
statistically significant difference between the highest elevation states and lowest
elevation states. Therefore, we just reconfirmed that the cancer incidence data for three
races of Black or African American, American Indian or Alaska Native, and Asian or
Pacific Islander, as a group, show no statistically significant difference for the highest
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elevation states and lowest elevation states. These are unique findings considering that
these three groups of races would need to be excluded from groups that would benefit
from lower bronchopulmonary cancer incidence at higher altitudes.
Social Impact
The association that I had found between altitude and bronchopulmonary cancer
incidence and mortality is for the Whites only group. My research inquiry contributes to
the expansion and development of a body of knowledge. A positive social change impact
of this study is that this study provides the groundwork for future studies to research what
exactly in the environment is causing the differences in bronchopulmonary cancer
mortality and incidence in the United States.
My study does create an immediate positive social change impact through the
very practical Bronfenbrenner’s (1977) ecological model. The immediacy of the positive
social change is brought about through the relevance of the individual component and
social environment component of the ecological model. Both the individual and social
circles do greatly influence patterns of disease and injury. The individual and social
environment both strongly shape our responses to these patterns of disease and injury.
At the individual level, the focus is on changing an individual’s knowledge and attitudes
to influence behavior. Social impact occurs not only when action is taken, but also when
knowledge is learned and when attitudes are changed. Individuals may learn of the
information concerning lower bronchopulmonary cancer incidence and mortality at
higher altitudes. They may relocate to higher elevation as a prophylactic against
bronchopulmonary cancer due to their increased awareness of this issue which may bring
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about an immediate positive social change. At the social environment level, interpersonal
relationships between friends, colleagues, peers, family members, and members of the
community influence behavior. The immediate positive social change, through the web
of these interpersonal networks and structures, expands and impacts even more people
through this social arrangement and framework.
Implication for Practice
The main aim of this study was to develop the understanding of the association
between altitude and bronchopulmonary cancer mortality and incidence by studying the
cancer mortality data and cancer incidence data for the lowest elevation and highest
elevation states within the United States from 2006 to 2014. I have done so by observing,
reporting, and analyzing new data from CDC WONDER.
My study strictly focuses on the association between altitude and
bronchopulmonary cancer incidence for new data. It also strictly focuses on the
association between altitude and bronchopulmonary mortality for new data. The
association that I had found between altitude and bronchopulmonary cancer incidence
and mortality for the Whites only group does not imply causality, nor does it mean that
altitude is a major influencer on bronchopulmonary cancer incidence and mortality.
Moreover, my study does not account for lifestyle (such as tobacco use), nor does my
study account for higher population densities, which lead to increased air pollution due to
increased use of motor vehicles, watercrafts, and aircrafts.
The theoretical framework for my study is the ecological model. The tenets of the
ecological model are depicted by the four levels of influence used in this model, and they
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serve as the four central components of this framework. They are the individual level,
social environment, physical environment, and public policy components.
At the public policy level, the focus is on changing policy to influence behavior.
Public health strategies may be implemented to increase awareness and understanding of
the association between altitude and bronchopulmonary mortality and incidence.
Without the implementation of public health strategies, it may be difficult to witness the
power and impact of the ecological model. Government agencies can promote and
distribute my novel finding of the beneficial outcomes for bronchopulmonary cancer
mortality and incidence via public health announcements on television, radio, and the
internet. The target audience would be only for the Whites only population of the United
States. At the same time, these policies and promotions should remind the target
audience of the responsibility to live healthy lifestyles such as avoiding tobacco. These
policies and promotions encouraging relocation for Whites to higher altitudes would then
have a better chance to succeed and lead to positive health outcomes.
Recommendations for Future Research
I believe my study has paved the way for an expanded research into collecting
bronchopulmonary cancer mortality and cancer incidence for all 50 states. My study
advances opportunities for future research for concept validation and theory
reinforcement. More research will be needed to refine and build up on my novel
findings. This next phase of research is important because we can rank the various states
according to their mean elevations. We can then plot each state’s bronchopulmonary
cancer mortality data against the mean elevation of each state. The data for each state
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should be controlled for age, sex, and race as well just as I had done in my study for the
six highest and the six lowest elevation states. There will be 51 data points (including the
District of Columbia) for each of the myriads of graphs that can be generated from
controlling for age, sex, and race. A linear regression analysis can then be done to see
how well the data fits the model. It would be very misleading to do a linear regression fit
for the data that I had studied on bronchopulmonary cancer mortality because my data
only dealt with the extremes, i.e., my data only dealt with the 6 highest elevation states
and the 6 lowest elevation states.
We can also plot each state’s bronchopulmonary cancer incidence data against the
mean elevation of that state. The data for each state should be controlled for age, sex,
and race as well just as I had done in my study for the six highest and the six lowest
elevation states. There will be 51 data points (including the District of Columbia) for
each of the myriads of graphs that can be generated from controlling for age, sex, and
race. A linear regression analysis can then be done to see how well the data fits the
model. It would also be very misleading to do a linear regression fit for the data that I
had studied on bronchopulmonary cancer incidence because my data only dealt with the
extremes, i.e., my data only dealt with the 6 highest elevation states and the 6 lowest
elevation states.
My study has also paved the way for future research to find out the reasons
behind why the three races, Black or African American, Asian or Pacific Islander, and
American Indian or Alaska Native, show no statistically significant difference in
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bronchopulmonary cancer mortality and cancer incidence for the highest elevation states
and lowest elevation states.
Conclusion
In this final chapter, I summarized my research findings, discussed the
implications for practice, explained the social impact, and made recommendations for
future research. This study provides the groundwork for future studies to research what
exactly in the environment is lowering the bronchopulmonary cancer mortality and
incidence specifically for the White population.
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